Upcoming event

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial

The LANCET Oncology, October 2021

Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)

Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

Off-clamp robot-assisted partial nephrectomy: how far shall we proceed?

Journal of Urology, September 2021

Percutaneous tumor ablation compared to partial nephrectomy for ct1a renal cancer: the impact of histologic variant

Journal of Urology, September 2021

longitudinal change of renal parenchymal volume preserved after partial nephrectomy in patients with preexisting chronic kidney disease

Journal of Urology, September 2021

shifting from planned off-clamp to on-clamp approach during partial nephrectomy: cross-analysis of two randomized trials

Journal of Urology, September 2021

Pseudoaneurysm of the renal artery following robotic-assisted partial nephrectomy: single-center analysis of predictive factors

Journal of Urology, September 2021